# ABS and Animal Breeding legislation → relationships and interactions

Elzbieta Martyniuk and Sipke Joost Hiemstra SANCO, 7 February 2017







## This presentation

- ABC of the Nagoya Protocol
- Regulation 511/2014 and Implementing act 2015/1866
- General scope
- Obligations of users
- Development of (sector-specific) guidelines for implementation of EU Regulation 511/2014
- Relevance of ABS for the animal breeding sector





# Convention on Biological Diversity (29 Dec 1993)

#### Objectives:

- conservation of biological diversity;
- sustainable use of its components;
- fair and equitable sharing of the benefits.
- New principle and concept:
  - genetic resources no longer 'heritage of mankind'; instead, states have sovereign rights over genetic resources;
  - access and benefit-sharing (ABS), through bilateral contracts on a case-by-case basis.





# Nagoya Protocol: 12 October 2014

#### Objective:


 further advance the implementation of the third objective of the CBD:

fair and equitable sharing of benefits arising from the utilisation of genetic resources

#### Important elements:

- Bilateral contracts: PIC and MAT on GR and associated TK
- Facilitating access: simple and transparent procedures
- Compliance of users
- Compliance of Parties









## **Important terms: CBD**

- Prior Informed Consent (PIC): approval, by the authorities of the country where access is sought, of access to and utilization of genetic resources; involvement of IPLC in case of TK associated with GR
- Mutually Agreed Terms (MAT) contract between two parties under a civil law including benefit sharing provisions









## **Important terms: Nagoya Protocol**

Utilisation of genetic resources: to conduct research and development on the genetic and/or biochemical composition of genetic resources, including through the application of biotechnology.

#### as defined in the CBD

- Genetic resources: genetic material of actual or potential value
- Genetic material any plant, animal, microbial or other origin containing functional units of heredity






# **Summary: ABC of the Protocol**

to GR and TK (PIC) Access (or no access regulations) Benefit bilaterally: according to MAT **Sharing** the GMBSM? monetary/non-monetary national legislation Compliance IRCC/checkpoints monitoring users


#### **PROVIDER** USER COUNTRY COUNTRY **GRs** Utilization of GRs PIC Competent National Certificate Authority Checkpoint(s): one or more must be effective should be relevant to the MAT utilization of genetic resources or -Terms of Use (e.g. to the collection of relevant Commercial or noninformation at, inter alia, any commercial) stage of research, development, innovation, pre-commercialization -Benefit-sharing (monetary or commercialization or non-monetary) **Benefit-sharing** Provide information on PIC, MAT, source of GRs, use of GRs Permit Notified to ABS Monitoring the utilization Clearing-House of genetic resources International Certificate of

Compliance

# State of ratification, 5th February 2017



# **ABS Clearing House**





23 JAN 2017

19 JAN 2017

22 DEC 2016





The two worlds of Nagoya – ABS legislation in the

El patentamiento de genes a cambio de la

Access and Benefit Sharing - Key Points for

The Interface between access and benefit-

información genética ¿una retór...

Policy Makers - Agriculture

sharing rules and BioTrade

formación de un cartel de países proveedores de









03 JAN 2017

BioTrade

21 NOV 2016

07 NOV 2016

12 OCT 2016





Addressing the intersection between the Nagoya

Protocol, access and benefit sharing rules, and

Survey, Collection and conservation of plant

Taller de Capacitación en Manejo del Centro de

genetic resources of the State of Qatar

Intercambio de Información en Acceso v

Participación en los Beneficios (C...





01 FEB 2017

Code of Conduct

Global Genome Biodiversity Network Guidance: **Best Practice** 

Global Genome Biodiversity Network Guidance:

Material Transfer Agreements

#### 21 NOV 2016

Utilization of genetic resources and associated traditional knowledge in academic research - A good practice guide for a...

#### 03 NOV 2016

Raizeiras


27 JUN 2016

Ogiek Bio Cultural Community Protocals (BCP)

### **IRCC: 50**

India: 46 Mexico: 1

South Africa: 2 Guatemala:1









# ABSCH-IRCC-IN-204353-1 Internationally recognized certificate of compliance constituted from information on the permit or its equivalent made available to the Access and Benefit-sharing Clearing-House

In accordance with Article 17, paragraph 2, of the Nagoya Protocol on Access and Benefit-sharing, a permit or its equivalent issued in accordance with Article 6, paragraph 3 (e) and made available to the Access and Benefit-sharing Clearing-House, shall constitute an internationally recognized certificate of compliance.

#### General Information

Issuing country

INDIA

Verification link (view latest version)

http://absch.cbd.int/database/ABSCH-IRCC-IN-204353

**ABS-CH Unique Identifier (UID)** 

ABSCH-IRCC-IN-204353-1

#### Issuing Authority

#### Competent National Authority

National Biodiversity Authority (NBA)

5th Floor, TICEL Biopark, CSIR Road, Taramani Chennai, Tamilnadu

600 113, India

Phone: +91 44 2254 2777

Fax: +91 44 2254 1200

Email: secretary@nbaindia.org, chairman@nba.nic.in, secretary@nba.nic.in

Website: http://www.nbaindia.org

#### Details of the permit or its equivalent

Reference number of the permit or its equivalent

India/NBA/Appl/9/684

Additional national references or identifiers

Application in Form-I for accessing ethno-medicinal knowledge of the Siddi community from Gujarat for research

Date of issuance of the permit or its equivalent

Date of expiry of the permit or its equivalent

27 Mar 2015

26 Mar 2018

#### Prior Informed Consent (PIC) Information

Confirmation that prior informed consent (PIC) obtained or granted

YES

Provider The person or entity that holds the right to grant access to the genetic resources in accordance with domestic legislation.

CONFIDENTIAL INFORMATION

Entity to whom PIC was granted

Ms Seema Solanki

Medical Anthropology and Ethno biology,

Research Scholar (-)

University of Kent Canterbury

United Kingdom of Great Britain and Northern Ireland

Phone: +91 9717032453

Email: seemasolanki.du@gmail.com, ss830@kent.ac.uk

#### Mutually Agreed Terms (MAT) Information

Confirmation that mutually agreed terms (MAT) have been established

YES

Additional information about the mutually agreed terms

- 1. The user shall not obtain any form of IPR based on the biological resources and /or associated knowledge accessed under this agreement in any manner without obtaining the prior approval of NBA under provisions of the Biological Diversity Act, 2002.
- 2. The applicant shall submit a report to NBA on the outcome of the research work.

#### Subject-matter

Subject-matter or genetic resources covered:

Accessing ethno-medicinal knowledge of the Siddi community from Gujarat for research

#### Information on the utilization of the genetic resource(s)

Type of use allowed by the permit or its equivalent

CONFIDENTIAL INFORMATION

Conditions for third party transfer:

The user shall not transfer or part with the biological resources and /or associated knowledge accessed under this agreement in any manner without obtaining the prior approval of NBA under provisions of the Biological Diversity Act, 2002.

#### Certificate History

	Date	Action	Author	Comment
	01 OCT 2015 11:52 AM	PUBLISHED	Hem Pande (hempande@nic.in)	Permit information published to the ABS clearing- house and certificate generated.

#### **Further Information**

Questions about the permit or its equivalent constituting an internationally recognized certificate of compliance should be addressed to the competent national authority issuing the permit or its equivalent. Additional information about the permit or its equivalent may be available in the Access and Benefit-Sharing Clearing House (http://absch.bdb.int/).

Questions about the Nagoya Protocol on Access and Benefit-sharing or the operation of the Access and Benefit-sharing Clearing-House may be directed to the Secretariat of the Convention on Biological Diversity

Secretariat of the Convention on Biological Diversity

413 rue Saint-Jacques, suite 800 Montreal, Québec, H2Y 1N9 Canada

Fax: +1 514 288-6588 Email: secretariat@cbd.int



## **UN Biodiversity Conference, Cancun, 2016**



Important decisions on:


**Synthetic biology** 

**Digital sequence information** 

**Article 10** 







































# FAO Commission on Genetic Resources for Food and Agriculture

#### A strong interest in ABS issues in relation to GRFA

- to contribute to negotiations under the CBD
- to consider impact of the Nagoya Protocol on GRFA
- to facilitate development of national ABS legislation (ABS Elements adopted by CGRFA in 2015)
- to develop explanatory notes for subsectors of GRFA
- to consider use of digital sequence information on GRFA for conservation and sustainable use and its implications for ABS







## **EU ABS law**



5.2014

EN

Official Journal of the European Union

I.

# REGULATION (EU) No 511/2014 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 April 2014

on compliance measures for users from the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization in the Union

(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty on the Functioning of the European Union, and in particular Article 192(1) thereof,

Having regard to the proposal from the European Commission,





# ABC of the Protocol and 511/2014


Access

Benefit
Sharing

Compliance

- Sovereign rights of MS over GR
- Not implemented at EU level
- Subject to contractual agreement (MAT) between user and provider
- Not implemented at EU level
  - EU ABS Regulation 511/2014:
- The same /requirements for users of GR and associated TK within the Union

## Key provisions of the EU ABS regulation



# **Art. 4: Obligations of Users**



- Due diligence a key concept in defining obligations of users
- Obligation to Seek, keep and transfer to subsequent users:
  - the IRCC
  - relevant information:

GR/TK associated with GR, date/place of access, source, any rights & obligations, PIC & MAT







# **Art. 7: Checkpoints**

### Two checkpoints:

- at the stage of **research funding** where research involves utilisation of GR and associated TK
- at the stage of **pre-commercialisation** (final stage of development of the product)

IT tool being developed by the COM to facilitate exchange of information (MS – EC – ABS CH)







## **Art. 9: Compliance checks:**

- Carried out by Member States
- Based on risk-assessment plans (periodically reviewed)
- Based on information received (substantiated complaints from the provider countries)
- Checks take into account implementation by the users of best practices





# EU Implementing Act 2015/1866

- Providing detailed rules on the implementation of Articles 5, 7 and 8 of the Regulation 511/2014
  - Register of collections
  - Check points: due diligence declarations in the case of research grants and product marketing
  - Application of best practices







# Scope of the EU ABS Regulation: Guidance document on the scope of application

- Material scope: GR and associated TK
- **Temporal scope**: applicable from 12 October 2014 (GR and associated TK must be accessed and utilised after this date)
- **Geographical scope**: applicable to GR and associated TK to be accessed in countries which have:
  - ratified the Nagoya Protocol
  - have adopted national ABS legislation (access measures)

(BUT users of GR and TK from Non-Parties should comply with national legislation or regulatory requirements of such a country and respect any MAT








# Application of 511/2014



- EU Regulation applies directly to
  - all EU MS
  - all users of all EU Member states
- National legislation needed to clarify issues like:
  - access measures
  - implementation framework (NCA)
  - monitoring system to check compliance of users
  - penalties





## Elements of 511/2014 & 1012/2016

	511/2014	2016/1012
<b>Scope</b> of the regulation	all livestock and all animal species	bovine, porcine, ovine, caprine and equine species
Conditions of entry into the Union of breeding animals	PIC and MAT and/ or IRCC issued by the CNA of the provider's country	under conditions that the rules applicable to trade in third countries are closely comparable to those the Union
Purpose of entry	utilisation: potentially in the future, single GR for R&D	placing on the internal market: breeding animals and their germinal products, a substantial volume
Post entry requirements for progeny	cutting point for benefit sharing, depends on MAT	only zootechnical, no further financial obligations







# **EU Guidance document for Animal Breeding sector DRAFT**



- Draft V2.0 of January 2017 under final discussion
- Content
  - Focus on classification of activities in relations to utilisation
  - Many examples listed to consider as cases within/outside the scope of the 511/2014
  - Background information on the sector (description, economic importance, organization, exchange practices... in Annex)
- Other sector-specific guidance documents under development since 2016







### **DRAFT EU Guidance - Case 1: OUT**



- Use of sequencing data from the public domain
- Use of DNA sequence data of animals of various species and breeds that have been made available in public databases (in association with scientific publications) in order to identify interesting traits and underlying sequences in the genetic resources studied. Such use is likely to increase with the availability of new technologies allowing fine-tuned changes in the genome (genome editing).
- The use of digital sequencing data often stored in publicly available databases may be considered to be out of scope of the ABS Regulation.





## **DRAFT EU Guidance - Case 2: OUT**

Taxonomic identification



- Describing and documenting the basic characteristics of an acquired GR at the species level (i.e. to answer the question to which species the acquired genetic resource belongs to) may form a basic and early step preceding breeding efforts, for example in the case of newly introduced wild fish species for the purpose of aqua farming, and in the case of rare companion animals. Such activity could be undertaken by any public or private actor, and is more likely to involve fish and companion animals than livestock.
- Taxonomic identification of genetic material, in the form of verification of received material and morphological analysis is not considered to constitute R&D.







### **DRAFT EU Guidance – Cases 3-5: IN**

- PRANCE OF THE PR
- Genotypic and phenotypic characterisation for the purpose of understanding genetic variation within and between breeds and breeding lines.
- Scientific research specifically performed on the genetic background of traits of interest, to analyse which genes, gene complexes or regulatory sequences and mechanisms governing their expression are involved.
- Scientific research on genetic abnormality, resulting from a causal mutation that may lead to a diagnostic test that may be commercialised.

These activities are considered to be R&D and hence to fall within the scope of the EU ABS Regulation.





# **DRAFT EU Guidance – Cases 6-10**

- Breeding activities using germplasm from external sources aimed at the genetic improvement of breeding material for the purpose of commercial sales.
- Breeding of genetic resources newly introduced from the wild for the purpose of aqua farming.
- Breeding of genetic resources newly introduced from the wild for the purpose of novel companion animals.
- Breeding of companion animals using newly introduced genetic resources.
- Genome editing at the single nucleotide level, directed at the introduction of one or more specific mutations for the purpose of improving traits of interest or to 'repair' genetic abnormalities.







## **DRAFT EU Guidance - Cases 6-10: IN**



- Breed improvement or creating new breeds or lines in livestock and in companion animals are considered R&D and hence to fall within the scope of the Regulation.
- The fact that such activity is considered as a standard activity does not warrant the conclusion that such activity does not qualify as research and development.
- Breeding of less studied aqua species/ novel companion animals lead to increased knowledge and create added value and potential benefits for the breeder.
- Improvement of animals or animal populations by genome editing is considered R&D and to fall within the scope of the Regulation. Whether such activity triggers any BS obligations depends on the status of the data used. Providing countries may have set conditions to the publication and use of DNA sequence data.





### **DRAFT EU Guidance - Case 11: OUT**



- Development and application of reproductive technologies (e.g. In Vitro Fertilization (IVF), semen sexing) to increase reproduction efficiency
- The development and application of reproduction technologies do not address the genetic resources contained in specimens. Results are normally species-specific but independent of the intra-specific diversity in a species. Therefore, the development and application of reproductive technologies do normally not constitute R&D on the animal genetic resources and hence are not in scope of the EU ABS Regulation.





## **DRAFT EU Guidance - Cases 12-13: OUT**

- Selling or trading breeding animals or other types of genetic material (semen) to customers in their own and other countries.
- Trading does not constitute R&D, and hence does not fall within the scope of the EU ABS Regulation
- Buying animals, semen or embryo's from commercial providers, including importers, to improve the genetic potential of their own farm herd and thereby to improve the value of their stock.
- As long as animals and/or their products are only sold as a commodity, this is normally considered to fall outside the scope of the EU ABS Regulation
- When farmers sell progeny as breeding animals for further use in breeding, case 6 would apply.





### **DRAFT EU Guidance – Cases 14-15: OUT**



- Exchange of genetic material of rare and traditional breeds between breeders, within breed associations or networks
- Trade or exchange between farmers and breeders within an association/network for the purpose of conservation of rare or traditional breeds is considered out of scope of the EU ABS Regulation
- Within-company across-country exchange
- This type of exchange may be characterised by dissemination of genetic progress rather than by marketing of the results of R&D, and the activity of the distributing entity would normally be considered to fall outside the scope of the EU ABS Regulation






### **DRAFT EU Guidance - Case 16: IN**



- Use of molecular information for breeds/animal traceability
- The use of molecular information derived from relevant animal genetic resources to develop methods for the purpose of traceability of a genetic resource and its products involves detailed study of the genome of individual animals for traits identified in the breeding objectives.
- Such activities lead to increased knowledge and create added value and potential benefits for the breeder. Such activities are considered R&D and to fall within the scope of the EU ABS Regulation.






### **DRAFT EU Guidance – Cases 17-18: OUT**



- Genetic resources as testing/reference tools
- Since the animal genetic resources is not the subject of research and development when it is used as a testing/reference tool, in such activity the animal genetic resource is considered to fall outside the scope of the Regulation
- Import of commodities
- Commodities are out of scope of the Regulation, whereas further R&D on such commodities would imply a change of intent in the use and qualify that activity as to be within scope of the EU Regulation, if the further use would involve R&D.






# Which activities are considered utilization/R&D?

#### General picture:


Breeding activities, selection, mating aimed at the genetic improvement of populations and to generate better offspring




Activities when AnGR are not the subject of Research and Development








# When ABS legislation becomes relevant...





#### Introduction of:

- New breeds/lines
- Individual breeding animals
- Any type of genetic material





# Is ABS legislation relevant for animal breeding sector in the EU?

- YES
- BUT short term impact limited
  - Introduction of breeding material, from countries that have or are developing ABS access legislation, has been limited
  - Rare examples of commercially successful introgression of exotic genotypes to mainstream breeds (e.g. Meishan pig) + negligible use of wild relatives







# Is ABS legislation relevant for animal breeding sector in the EU?

- Gene flows may change in the future
  - Driven by technology genomic research, genome editing
  - Driven by climate change → adaptive traits


#### **MOREOVER**

- Difficulties to establish ownership of a breed: cumulative genetic progress
- A frequent exchange of genetic material for scientific research collaboration (public /public-private)









# Izrael ARO, **Volcani Center**




#### Assaf:5/8 Awassi 3/8 East Friesian





# **Awassi & Assaf**

Zarate i wsp., 2006







### Issues to consider

At present: no interest within a breeding industry to use exotic genetic resources in commercial breeding programmes

Gene flow North-North and North-South

- Potential access legislation to livestock genetic resources in MS (not the case so far but cannot be excluded)
- Import of individuals/ germinal material of native breeds from third countries that have no rules applicable to trade that are comparable to those the Union (derogation?)
- Use of digital genetic sequence data on livestock GR

(a process set under the CBD COP 13 and the FAO CGRFA to better understand the scope of use and ABS implications)



### **DRAFT EU Guidance – Unresolved issues**

Cut-off point for applying DD [Benefit Sharing]

• F1: 50%

• F2: 25%

• F3: 12.5%

• F4: 6.25%

of the genome of the genetic resource

accessed from a provider country

One possible interpretation: Due diligence obligations under the EU ABS Regulations only extend to genetic resources resulting from breeding activities wherein a genetic resource accessed from a provider country is represented with a minimum of 6.25% or wherein a trait of market value has been incorporated.

All obligations on the use of certain genetic resources exhaust 20 years after the first introduction of a progenitor genetic resource.







## **Summary and conclusions**

- Generally animal breeding should be considered as utilization/R&D
- In case of importing GR for R&D, after 12 October 2014 from countries being Parties to the Nagoya Protocol and having access legislation – PIC and MAT are required
- Recommendation to negotiate broad ABS arrangements between provider and the first user
- Transactions to subsequent users (next generations) may trigger obligations of the purchaser towards the original providing country
- Low/no demand in EU for GR from the South impact of ABS on animal breeding currently limited, but exchange patterns may change







# Thank you for your attention!

